Terdapat penemuan terbaru dalam kanser paru-paru bukan sel kecil. Sejenis imunisasi yang dapat merawat barah paru-paru sel bukan sedikit (NSCLC) telah mengalami persetujuan klinikal tahap 3 dan mempunyai kesan terapi yang besar terhadap penyakit paru-paru sel bukan kecil. Sekarang boleh diakses di beberapa negara.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung vaksin barah boleh meningkatkan kadar kelangsungan hidup pesakit dengan peringkat relapsed dan lanjutan (peringkat IIIB/IV) NSCLC.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Setelah kerangka yang tidak dapat difahami menghasilkan antibodi eksplisit terhadap an antigen, ia dapat membuat antibodi terhadap keunikan antigen utama, yang dapat mengawal kerangka tahan dari dalam. Apabila diberi imunisasi terhadap pertumbuhan malignan paru-paru ini imunisasi, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumor antigen.
Telah terbukti secara klinikal bahawa penyakit paru-paru imunisasi sangat bertahan dan mempunyai pelaksanaan yang lebih baik. Banyak simptom asas berlaku hanya di kawasan setempat (laman infus) dan biasanya lembut dan panjangnya pendek. Tidak kira sama ada antibodi diberikan kepada pesakit setelah keadaannya hancur, daya tahan umum mereka bertambah baik.
Pada masa ini, imunisasi pertumbuhan malignan paru-paru seperti ini tidak dipromosikan di India.
